Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Sep 1;66(5 Suppl):1025-8.
doi: 10.1002/cncr.1990.66.s5.1025.

Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer

E H Cooper  1 , T G Armitage, M R Robinson, D W Newling, B R Richards, P H Smith, L Denis, R Sylvester
Affiliations

Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer

E H Cooper et al. Cancer. .

Abstract

Serum prostate-specific antigen (PSA) levels were studied in the EORTC trial of zoladex plus flutamide versus orchidectomy in metastatic prostatic cancer. Forty-four of 60 patients had a decrease of PSA to less than or equal to 10 ng/ml at 3 to 6 months after treatment. The combination of a PSA less than 10 ng/ml after 3 to 6 months treatment and less than 15 spots on the bone scintigram at entry gave the highest probability of not having progressed by 24 months. A rising PSA anticipated bone progression by 6 to 12 months in 13 of 28 patients (46%). The PSA at entry to the trial was related to survival; a discriminant of 300 ng/ml distinguished a poor and better risk group. The lowest level of PSA reached during the first 6 months of treatment was also a univariate survival factor.

PubMed Disclaimer

MeSH terms